Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Notes Lack Of Proof For Cancer Risk, But Lantus Isn't Out Of The Woods Yet

This article was originally published in The Pink Sheet Daily

Executive Summary

Commercial impact on the top-selling insulin is questionable, as 2009 studies showing the risk had already been seen as sketchy and did not appear to dent sales or competitive profile.
Advertisement

Related Content

Doctors Urge Caution In Interpreting FDA’s SGLT2 Warning
Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
Pfizer Teams Up With Biocon In Bid to Dominate Global Biosimilar Insulin Market
Sanofi Counts FDA As New Supporter In Lantus Cancer Scare
Will Sanofi's Lantus Survive Cancer Scare? Studies Suggest a Worrisome Link
Will Sanofi's Lantus Survive Cancer Scare? Studies Suggest a Worrisome Link

Topics

Advertisement
UsernamePublicRestriction

Register

PS071698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel